Neuroendocrine and Metabolic Disorder Solutions
Changing the Face of Oral Absorption Drugs
OUR PIONEERING LIP'RAL TECHNOLOGY ENABLES EFFICIENT ABSORPTION OF WATER INSOLUBLE DRUGS.
Our unique technology, coupled with our product development pipeline entails repositioning of established drugs with significantly improved patient compliance through an efficient 505(b)(2) regulatory pathway strategy. We are focused on metabolic and endocrine disorders such as:
- Liver Disease (NASH)
- Low Testosterone (Hypogonadism)
- Recurrent Pre-Term Birth
- Postpartum Depression
Press Releases
Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity
LPCN 2401 treatment resulted in statistically significant body composition improvement in men Increased lean mass (LM) by 4.4% and decreased fat mass (FM) by 6.7% Reduced android fat (AF) by 4.1%...
Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis
Met primary and Hepatic Encephalopathy (HE) endpoints in Phase 2 study Increase in Skeletal Muscle Index (SMI) observed at Week 24 was maintained through 52 weeks Participants on placebo increased...